Key result
Pterostilbene alleviates doxorubicin-induced cardiotoxicity by inhibiting IL-6/STAT3-driven cardiomyocyte pyroptosis.
Why the study?
Pterostilbene has demonstrated cardioprotective potential in doxorubicin-induced cardiotoxicity, but its role in doxorubicin-induced pyroptosis remains unclear.
Does pterostilbene prevent doxorubicin-induced cardiotoxicity and cardiomyocyte pyroptosis in preclinical models?
Does pterostilbene prevent doxorubicin-induced cardiotoxicity and cardiomyocyte pyroptosis in preclinical models?
Pterostilbene demonstrates significant therapeutic potential in mitigating doxorubicin-induced cardiotoxicity by interrupting the cardiomyocyte pyroptosis-M1 macrophage polarization vicious cycle.
Should not yet change doxorubicin cardioprotection practice; hypothesis-generating for pterostilbene in preclinical cardiotoxicity models.
Doxorubicin (DOX)-induced cardiotoxicity (DIC) is a major dose-limiting complication of chemotherapy, in which pyroptosis is considered a key pathological mechanism. The natural stilbene compound pterostilbene (PTE) has demonstrated cardioprotective potential, but its role in DOX-induced pyroptosis remains unclear. This study, using both in vitro H9C2 cardiomyocyte and in vivo C57BL/6 mouse models of DIC, confirmed that PTE effectively inhibits DOX-induced cardiomyocyte pyroptosis and alleviates cardiac injury. Mechanistically, DOX activates the IL-6/STAT3 signaling pathway, promoting the nuclear translocation of phosphorylated STAT3 (pSTAT3). CUT&Tag and dual-luciferase reporter assays further revealed that activated STAT3 directly binds to the core promoter regions of the caspase-3 and Gasdermin E (GSDME) genes, thereby upregulating their expression at the transcriptional level and ultimately activating the caspase-3/GSDME-mediated pyroptosis pathway. PTE effectively blocks this pyroptotic execution pathway by inhibiting the activation of the IL-6/STAT3 pathway. Furthermore, this study elucidated a critical interaction between cardiomyocytes and immune cells: GSDME-mediated cardiomyocyte pyroptosis releases various soluble factors, with IL-6 being a key cytokine that drives the polarization of macrophages toward the pro-inflammatory M1 phenotype, thereby amplifying the myocardial inflammatory response. By inhibiting cardiomyocyte pyroptosis, particularly by reducing IL-6 release, PTE effectively interrupts this "cardiomyocyte pyroptosis-M1 macrophage polarization" vicious cycle and restores myocardial homeostasis. In summary, our research elucidates a signaling cascade driving DOX-induced cardiotoxicity: IL-6/STAT3-caspase-3/GSDME. We confirmed that PTE is an effective inhibitor of this pathway, not only directly protecting cardiomyocytes but also suppressing the subsequent pyroptosis-driven inflammatory response, thereby highlighting its significant therapeutic potential in mitigating DIC.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2026) studied this question. Pterostilbene inhibits the IL-6/STAT3-caspase-3/GSDME pathway, reducing doxorubicin-induced cardiomyocyte pyroptosis and macrophage M1 polarization, alleviating cardiotoxicity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: